An existing blood pressure drug, guanabenz, has shown promise in slowing the progression of a rare and potentially fatal brain disease in children, according to a study led by Amsterdam University Medical Centers (Amsterdam UMC). This groundbreaking research, published in The Lancet Neurology, offers a glimmer of hope for families affected by Vanishing White Matter (VWM), a hereditary neurodegenerative disorder that primarily affects young children. With no approved treatment currently available, the study's findings are particularly significant.
VWM is a devastating condition, causing progressive loss of motor and intellectual abilities and often leading to early death. The study followed 67 children with VWM who received guanabenz and compared their disease progression over three years with that of 66 children with similar disease severity from an international registry who had not received the drug. The results were remarkable.
Children treated with guanabenz showed improved outcomes, becoming less dependent on wheelchairs and experiencing slower disease progression compared to the untreated group. This is a significant breakthrough, as it demonstrates that a fatal brain disease in children can be influenced and potentially managed.
The study's lead author, Marjo van der Knaap, emphasizes the importance of recognizing and managing side effects, which are common in young children. Hallucinations, drowsiness, constipation, and low blood pressure were observed, but these side effects were generally manageable and temporary. This is crucial, as it ensures that the treatment can be continued without causing undue harm to the children.
However, the researchers also caution that guanabenz is not a cure for VWM. The beneficial effects appear to disappear after treatment is discontinued, and the study did not include an untreated control group. These limitations highlight the need for further research and a deeper understanding of the drug's long-term effects.
Despite these considerations, the study's findings are a significant step forward in the fight against VWM. The ongoing follow-up study, which will monitor the children over a longer period and investigate higher doses of guanabenz, holds promise for further advancements in treatment. With an estimated one in 100,000 children worldwide affected by VWM, this research could have a profound impact on the lives of countless families.
